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ABSTRACT 
Aging is a complex process affecting all people. Intense research is 
applied to elucidate the biological basis of aging and disease that develop with 
aging. Studies of progeroid syndromes, where aging happens in an accelerated 
speed, might be useful to understand the molecular mechanisms in 
physiological aging. Hutchinson-Gilford progeria syndrome (HGPS or 
progeria) is a very rare, fatal genetic disease, with an incidence of 1 in 4-8 
million live births, which causes segmental premature aging in children. 
Affected individuals are born looking healthy, but develop symptoms of 
disease within their first years of life. Signs of progeria include growth 
retardation, loss of body fat and hair, skin changes, stiffness of joints, hip 
dislocations and generalized atherosclerosis and cardiovascular disease. 
Children with HGPS die of heart disorders or stroke at an average age of 13 
years. The aim of this thesis is to increase the understanding of the molecular 
mechanisms underlying progeria. For this purpose, we developed tissue-
specific inducible mouse models for the most common HGPS mutation in the 
LMNA gene (c.1824C<T, p.G608G). 
We demonstrate that the disease pathology in HGPS is reversible in a 
mouse model with keratin 5-targeted transgenic expression of the HGPS 
mutation. The mice had a progressive phenotype with similar abnormalities to 
those seen in the skin and teeth of HGPS patients. These abnormalities 
improved in mice following 6 and 13 weeks of suppressed expression of the 
HGPS mutation. Our results give hope for the future development of 
treatments for children with HGPS. 
We report our negative experience with a previously functional 
transactivator mice that failed to target the expression of the lamin A 
minigenes to the bone. To share this result with the scientific community will 
help to raise caution and to point out the importance for controls. 
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LIST OF ABBREVIATIONS 
HGPS Hutchinson-Gilford progeria syndrome 
AR Antigen retrieval 
BMD Bone mineral density 
CMT2 Chartoc-Marie-Tooth disease type 2B1 
DCM Dilated Cardiomyopathy 
Dox Doxycycline 
DXA Dual energy x-ray absorptiometry 
EDMD Emery-Dreifuss Muscular Dystrophy 
ER Endoplasmatic reticulum 
FPLD Familial Partial Lipodystrophy 
FTIs Farnesyl transferase inhibitors 
IHC Immunohistochemistry 
INM Inner nuclear membrane 
IRES Internal ribosome entry site 
K5tTA Keratin 5 tetracycline transactivator 
LGMD Limb-Girdle Muscular Dystrophy 
LINC Linker of nucleoskeleton and cytoskeleton complex 
MADA Mandibular Dysplasia type A 
NPC Nuclear pore complex 
NSE-tTA Neuron specific enolase tetracycline transactivator 
ONM Outer nuclear membrane 
PHH3 Phospho-histone H3 
pQCT Peripheral quantitative computed tomography 
pTRE Tetracycline responsive promoter element 
RD Restricted Demopathy  
rtTA Reverse tetracycline responsive transcriptional transactivator 
Sp7-tTA Osterix tetracycline transactivator 
TOR Target of rapamycin 
TRAP Tartrate-resistant acid phosphatase 
tTA Tetracycline responsive transcriptional transactivator 
TUNEL Terminal transferase dUTP nick end labelling 
α1p-rtTA Collagen type 1α1 reverse tetracycline transactivator 
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1 BACKGROUND 
Exploring the molecular and cellular mechanisms of Hutchinson-
Gilford Progeria Syndrome (HGPS) in animal models will help elucidate the 
pathophysiology of the disease in patients with this rare condition and thus 
lead to improved treatment options for affected individuals. HGPS affects 
only 1 in 4-8 million live born and the disease is present in all ethnic 
backgrounds throughout the world (Hennekam 2006). Signs of accelerated 
aging in several, but not all tissues and organ-systems, characterize HGPS 
and define it as a segmental premature aging disorder (DeBusk 1972, Brown 
1992). Understanding the molecular and cellular mechanisms of HGPS may 
thus help to uncover general principles of the aging process and diseases that 
develop with aging. HGPS is caused by a de novo single point mutation in 
exon 11 of the LMNA gene (De Sandre-Giovannoli et al. 2003, Eriksson et al. 
2003).  
 
1.1 LAMINS 
Lamins are intermediate filament proteins that polymerize and form the 
lamina network underlying the inner nuclear membrane (Fisher et al. 1986, 
Aebi et al. 1986, Lin and Worman 1993). The LMNA gene codes for the two 
major isoforms of the A-type lamins, lamin A and lamin C, by alternative 
splicing. Lamin A is encoded by exon 1-12 and lamin C is encoded by exon 1-
10 (Figure 1) (Fisher et al. 1986). A-type lamins are only expressed in terminal 
differentiated cells. In mice, lamin A and C first appear at embryonic day 12 in 
muscle cells of the trunk, head and the appendages. Three days later, they are 
also seen in the cells of epidermis. In the simple epithelial of lung, liver, kidney 
and intestine, as well as in the heart and the brain, lamins A and C do not 
appear until well after birth (Röber et al. 1989). Two minor additional isoforms, 
laminAΔ10 and lamin C2, have also been identified. The LaminAΔ10 protein 
lacks exon 10 compared with lamin A and has been found in the normal colon 
and in various carcinoma cell lines (Machiels et al. 1996). Lamin C2 differs in an 
alternative exon 1 compared to lamin C and is expressed in germ cells and 
fibroblasts (Furukawa and Hotta 1993, Rodríguez et al. 2009). In addition to the 
A-type lamins, there are also the B-type lamins. LMNB1 encodes lamin B1 
while LMNB2 encodes lamin B2 and the minor isoform lamin B3 (Dechat et al. 
2010). B-type lamins are expressed in all cells during development and in adult 
tissues. A- and B- type lamins share structural features of having a central α 
helical rod domain flanked by a small non-helical amino N-terminal sequence 
and a larger C-terminal globular domain (Figure 1) (Fisher et al. 1986). Lamin 
A, B1 and B2 are expressed as prelamins carrying a C-terminal CAAX motif 
and need to undergo post-translational modification including farnesylation 
and methylation to become mature lamins. Lamin C does not have a CAAX 
motif and does not require further modification (Figure 1) (Stuurman et al. 
1998). Mature lamin B1 and B2 remain permanently farnesylated and 
carboxymethylated (Stuurman et al. 1998) while prelamin A gets further 
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processed and mature lamin A lacks the C-terminal farnesylated and 
carboxymethylated modification (Corrigan et al. 2005).  
Figure 1. Schematic picture of the LMNA gene and the protein products lamin C and prelamin 
A. In the C-terminal globular tail domain prelamin A has a CAAX motif, which is absent in 
lamin C. The drawing was inspired by Burke and Stewart 2006 and Capell and Collins 2006. 
 
1.2 THE NUCLEAR LAMINA 
The nuclear envelope separates the cytoplasmic cell content from the cell 
nucleus (Figure 2). The interaction of the different cell compartments is highly 
regulated by nuclear membrane domains. The inner and outer nuclear 
membranes build together with the nuclear pore complexes (NPC), a complex 
regulatory protein network for the nucleo/cytoplasmic transport of proteins 
and RNA. The outer nuclear membrane (ONM) is physically connected with 
the endoplasmatic reticulum and shares many of its proteins. The inner nuclear 
membrane (INM) embeds numerous integral membrane proteins and is also 
connected to the underlining nuclear lamina. This lamina consists of polymers 
formed by the A- and B-type lamins (Strelkov et al. 2004). Polymerization of A- 
and B-type lamin homodimers takes place separately, but the forming 
filamentous networks interact with each other (Sullivan et al. 1999, Muchir et al. 
2000, Vergnes et al. 2004, Shimi et al. 2008). The nuclear lamina is disassembled 
and reassembled by phosphorylation and dephosphorylation during mitosis, 
along with the rest of the nuclear envelope (Hutchinson et al. 2001). The lamina 
meshwork plays an important role in the nuclear architecture by determination 
of the shape and mechanical properties (Furukawa and Hotta 1993, Sullivan et 
al. 1999, Liu et al. 2000, Goldman et al. 2008). The anchoring of chromatin and 
the correct localization of the nuclear pore complex in the nuclear envelope are 
additional important functions of the lamina. The minor fraction of the 
nucleoplasmic lamins is believed to influence DNA replication and 
transcription (Dechat et al. 2008). Lamins have been shown to play a role in the 
translocation of transcriptional regulators and to have an impact on gene 
expression (Hutchison 2002, Burke et al. 2002, Mounkes and Stewart 2004, 
Maraldi et al. 2011). Several studies have identified the interaction and binding 
of various proteins, including lamina-associated proteins (LAP 1 and Lap2α) 
(Foisner and Gerace 1993, Dechat et al. 2000), Emerin (Clements et al. 2000), the 
SUN proteins (SUN1 and SUN2) (Crisp et al. 2006), the nuclear envelope 
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spectrin repeat proteins (nesprin 1 and 2) (Mislow et al. 2002, Zhang et al. 2002), 
actin (Sasseville and Langelier 1998), pRb (retinoblastoma gene product) 
(Ozaki et al. 1994) and SREBP (sterol regulatory element-binding protein 1) 
(Lloyd et al. 2002). Furthermore lamins bind with one or more components of 
RNA polymerase II dependent transcription complexes and DNA replication 
complexes (Spann et al. 1997). The linker of nucleoskeleton and cytoskeleton 
complex (LINC) provides a physical connection between the nucleoskeleton 
and the cytoskeleton and its localization to the nuclear envelop depends on the 
lamins (Méjat and Misteli 2010). At the inner nuclear membrane the LINC 
complex depends on the SUN proteins. All SUN proteins contain a C-terminal 
transmembrane domain and a N-terminal domain that interacts directly with 
A-type lamins (Crisp et al. 2006). Nesprins are components of the LINC 
complex at the outer nuclear membrane where nesprin 1 and 2 bind to the actin 
cytoskeleton. The nesprins are also in connection with the SUN proteins by 
their transmembrane KASH (Klarsicht/ANC/Syne homologue) domain 
(Haque et al. 2006). Emerin, another lamin binding protein, also binds to 
nesprin, thus providing an additional connection between the lamins and the 
cytoskeleton (Zhang et al. 2002, Warren et al. 2005). The physical bridging of the 
nuclear lamina with the cytoskeleton has a major impact on cellular functions 
including cytoskeleton organisation, organelle positioning and cellular division 
(Méjat and Misteli 2010).  
Figure 2. Schematic picture of the nuclear envelope and the nuclear lamina. 
The lamina filaments (lamin A, C and B) located underneath the inner nuclear membrane 
(INM) interact with several trans-membrane proteins. Lamins play a role in anchoring of 
chromatin and the correct localization of the nuclear pore complexes (NPC). Through the 
binding of SUN domain proteins the lamina is also active in the linker of nucleoskeleton and 
cytoskeleton complex (LINC) involving KASH domains as well as Nesprin 1 and 2 and thereby 
establish a physical connection to the cytoskeleton (Actin). The drawing was inspired by 
Goldman et al. 2002 and Burke and Stewart 2006. 
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1.3 LAMINOPATHIES 
There are more than 10 different heritable conditions known to be due to 
mutations in the LMNA gene. These disorders are collectively named 
laminopathies and are often subdivided based on their shared phenotypes into 
four distinct categories: muscular dystrophies, lipodystrophies, neuropathies 
and segmental progeroid syndromes (Figure 3). There are more the 200 
mutations associated with these conditions and the disease mechanisms are 
still far from clear (Capell and Collins 2006, Worman et al. 2010).  
Muscular dystrophies include Emery-Dreifuss Muscular Dystrophy 
(EDMD), Limb-Girdle Muscular Dystrophy (LGMD) and Dilated 
Cardiomyopathy (DCM). The muscular dystrophies are characterized by 
progressive skeletal muscle weakness, also affecting the heart. Defects in 
muscle proteins, death of muscle cells and gradual wasting of the muscles with 
replacement by scar tissue and fat are typical clinical features. Patients with 
EDMD show slowly progressive contractures in childhood and teenage years. 
Muscle weakness and wasting starts in the distal limb muscles. Most patients 
also suffer from cardiac conduction defects and arrhythmias (Bonne et al. 1999, 
Morris 2001). Slowly progressive shoulder and pelvic muscle weakness and 
wasting followed by development of contractures and cardiac disturbances are 
typical for LGMD (Muchir et al. 2000). In DCM affected individuals display 
impaired contractility, arrhythmias and conduction defects. The muscle 
weakness in DCM is a cardiac-specific dystrophy without any affects on the 
skeletal muscle (Fatkin et al. 1999).  
The generalized or localized loss of body fat represents the typical clinical 
features of the lipodystrophies, like Familial Partial Lipodystrophys (FPLD), 
generalized Lipodystrophy type 2 and Mandibular Dysplasia typ A (MAD). In 
FPLD loss of subcutaneous white adipose tissue is seen in the extremities, the 
trunk and the gluteal region while the face, neck and abdominal region 
accumulates fat cells. FPLD (Peters et al. 1998, Hegele et al. 2005) and also 
generalized Lipodystrophy type 2 (Csoka et al. 2004) are associated with an 
increased risk of early endpoint atherosclerosis and the development of 
metabolic diseases like high blood levels of triglycerides (hyperglyceridemia) 
and insulin resistance, leading to diabetes. Clinical characteristics for MAD 
include general lipodystrophy, delayed closure of cranial sutures, dental 
crowding, joint contractures, mandibular and clavicular hypoplasia, 
acroosteolysis and insulin resistance. MAD patients also show short stature 
and alopecia (Novelli et al. 2002, Simha et al. 2003).  
Chartoc-Marie-Tooth disease type 2B1 (CMT2) is a neuropathy that 
affects the nerves that control the muscles. CMT patients slowly lose normal 
use of their extremities as the nerves degenerate and the muscles in the 
extremities become weakened because of the loss of stimulation by the affected 
nerves (De Sandre-Giovannoli et al. 2002).  
Under the category of the segmental progeroid syndromes are atypical 
Werner syndrome, Restrictive Demopathy (RD), classical and atypical HGPS. 
Werner syndrome is also known as progeria of the adult with death first 
occurring in the fifth or sixth decade in life due to atherosclerosis or neoplasia. 
Growth retardation manifesting from the second decade, cataracts, type 2 
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diabetes, osteoporosis, alopecia, sclerodermateous skin, loss of adipose tissue 
and increased tendency for cancer are typical clinical features for Werner 
syndrome (Werner 1985). Classical Werner syndrome is caused by mutations 
in the WNR gene, which encodes a RecQ helicase (Yu et al. 1996) Atypical 
Werner syndrome has similar features as classical Werner syndrome but is 
caused by mutations in the LMNA gene (Chen et al. 2003). Restrictive 
Dermopathy (RD) is a lethal tight skin contracture syndrome. Intrauterine 
growth retardation, joint contractures, tight and rigid skin and prominent 
vessels are typical for this neonatal disease. Affected individuals die due to 
pulmonary hypoplasia and subsequent respiratory insufficiencies during 
gestation or early after birth (Navarro et al. 2004, Navarro et al. 2005, Moulson 
et al. 2005, Burke and Stewart 2006).  
Figure 3. Schematic presentation of the laminopathies in four different categories: neuropathy, 
muscle disorder, lipodystrophy and progeroid syndrome. The clinical characteristics of MADA 
include lipodystrophic features as well as features implicated in segmental progeroid 
syndromes. 
 
1.4 HUTCHINSON-GILFORD PROGERIA SYNDROME 
Hutchinson-Gilford Progeria Syndrome (HGPS, progeria, 
OMIM#176670) is an extremely rare genetic disorder affecting one in 4-8 
million live births (DeBusk 1972) and it is classified as a segmental progeroid 
syndrome (Brown 1979, Brown et al. 1985, Sarkar and Shinton 2001). Affected 
individuals appear normal at birth and develop the first symptoms of disease 
usually within the first two years of life. Growth retardation together with 
dermatological changes like scleroderma and loss of subcutaneous fat are the 
early indications. The skin tightens over the abdomen and can restrict motion. 
Regional changes with wrinkled, thin, dry and atrophic skin, with signs of 
hyperkeratosis and hyperpigmentation, are found. Children usually gradually 
develop complete alopecia by the age of 3 years (DeBusk 1972, Gillar et al. 1991, 
Erdem et al. 1994, Jansen and Romiti 2000, Sarkar and Shinton 2001, Ackerman 
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and Gilbert-Barness 2002, Sevenants et al. 2005, Hennekam 2006, Merideth et al. 
2008). Short stature, low weight, prominent scalp veins and eyes, a pyriform 
chest, a high-pitched voice, a small and beaked nose, dental crowding and oral 
soft tissue alteration, thin lips and dystrophic fingernails are additional clinical 
features. Affected children do not enter puberty and lack sexual maturation 
(Hennekam 2006). The intellect of HGPS patients is unaffected and affected 
children do not develop signs of senility, cataract, cancer or metabolic diseases 
(DeBusk 1972, Stables and Morley 1994, Sarkar and Shinton 2001, Hennekam 
2006, Mazereeuw-Hautier et al. 2007, Merideth et al. 2008, Domingo et al. 2009). 
With increasing age, affected children develop shortness of breath with 
exertion, increased pulse rate and high blood pressure. The most common 
causes of death are heart failure and stroke at a median age of 13 years, ranging 
from about 8-21 years (Baker et al. 1981, Shozawa et al. 1984). Autopsy studies 
have shown abnormalities in the blood vessel layers with small diameters of 
the intima and media and increased tunica thickness. Histological observations 
include extensive loss of smooth muscle cells and their replacement with 
fibrous tissue (Markous et al. 1962, DeBusk 1972, Stehbens et al. 1999, Stehbens 
et al. 2001, Ackerman and Gilbert-Barness 2002, Nair et al. 2004, Gordon et al. 
2005, Hennekam 2006, Merideth et al. 2008).  
 
1.4.1 Skeletal phenotype in HGPS 
The disease progression in HGPS includes several developmental 
abnormalities of the skeleton. Growth retardation with short stature and low 
weight is a clinical feature that is always present (Badame 1989). A horse-riding 
stance is described, as the patients typically stand with flexed knees and 
increased distance between the thighs. In motion affected children display a 
wide based, shuffling gait. Decreased mobility is associated with joint stiffness 
usually starting in knees, followed by elbows, phalanges and hips. The limbs 
appear very thin with prominent joints (Moen 1982, Hennekam 2006).  
One of the earliest abnormal findings is acro-osteolysis, the distal resorption of 
fingers and toes, which gets more severe with disease progression (de Paula 
Rodrigues et al. 2002, Gordon et al. 2007). Roentgenographic analysis of the 
skull and facial bones reveals an overall decreased size and thinning of facial 
bones together with reduced head circumferences. The size of the cranial vault 
is normal compared to brain size, but appears relatively large compared to the 
decreased size of the facial bones. A glyphic beaked nose or convex nasal 
profile is a common characteristic of the facial features (Badame 1989, de Paula 
Rodrigues et al. 2002). The chin becomes smaller with an increased angle of the 
mandibular leading to dental crowding and double rows of teeth (Hennekam 
2006). Among the oral abnormalities, delayed tooth eruption, dysmorphic teeth 
and hypodontia, have been reported (Merideth et al. 2008, Domingo et al. 2009). 
The upper part of the thorax often gradually narrows with progressive 
osteolysis of the clavicles, as well as thinning and tapering of the ribs ending in 
a pyramidal thorax configuration and pear shaped appearance (Hennekam 
2006, Gordon et al. 2007, Merideth et al. 2008). Spinal malformations include 
dislocated shoulders, decreased spinal flexion, kyphosis and scoliosis. The 
vertebral bodies display an ovoid and fish-mouth appearance. Hip dislocations 
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are characteristic for coxa valga, a deformity caused by an increased angle 
between the femoral neck and shaft and coxa plana, the disintegration of the 
capital femoral head leading to diminished blood supply of the bone and 
subsequent osteonecrosis (de Paula Rodrigues et al. 2002, Hennekam 2006, 
Gordon et al. 2007). The long bones are described to be more slender and 
bowed (Hennekam 2006). Earlier reports of clinical investigators interpreted 
the abnormal mineralization observed on radiographs from HGPS patients as 
focal osteoporosis restricted to the distal ends of the long bones (Gordon et al. 
2007). Others regarded the decreased bone mineral density (BMD) as 
histopathological features that score in the osteoporotic range (Merideth et al. 
2008). Recently a study utilizing dual energy x-ray absorptiometry (DXA) and 
peripheral quantitative computed tomography (pQCT) concluded that the 
pathological conditions represent a unique skeletal dysplasia, which differs 
from defective bone turnover, the normal cause for senile osteoporosis 
(Gordon et al. 2011). In addition, this study analyzed the daily caloric and 
nutrient intake and showed that the skeletal pathology could not be ascribed to 
malnutrition-induced bone loss. Along with normal bone age, neither 
proliferative changes, like osteoarthritis or rheumatism, nor abnormalities in 
growth plate development and fracture risks were found as orthopedic aspects 
of progeria (Gordon et al. 2007, Gordon et al. 2011).  
 
1.5 MOLECULAR BASIS IN HGPS 
The majority of the classical cases of HGPS are caused by a de novo single 
point mutation within exon 11 of the LMNA gene (c.1824C<T, p.G608G). The 
mutation activates a cryptic splice site, removing 150 nucleotides of exon 11, 
and results in a prelamin A protein, named progerin, with an internal deletion 
of 50 amino acids (De Sandre-Giovannoli et al. 2003, Eriksson et al. 2003). Since 
the mutation is located in exon 11, it will just affect the lamin A protein. 
Atypical HGPS describes diseases with similar progeroid features of classical 
HGPS, which are caused by missense mutation in the LMNA gene, but do not 
result in abnormal splicing within exon 11 (Eriksson et al. 2003, Csoka et al. 
2004, Verstraeten et al. 2006, Liang et al. 2009). 
 
1.5.1 Post-transcriptional processing of prelamin A in HGPS 
Lamin A is synthesized as a precursor molecule, prelamin A. Prelamin 
A is modified in different processes before it becomes mature lamin A (Figure 
4) (Lutz et al. 1992, Sinensky et al. 1994, Hennekes et al. 1994). Farnesylation of 
the cysteine residue of the CAAX box initiates a sequence of processing steps 
starting with the -AAX motif cleavage by the endopeptidases Rce1 (Ras-
converting enzyme 1) or Zmpste24 (FACE1 in humans) (Beck et al. 1990, Zhang 
and Casey 1996). The cleavage step is followed by carboxymethylation of the 
C-terminal cysteine by isoprenylcysteine carboxy methyltransferase (Icmt) 
(Winter-Vann and Casey 2005). The endoprotease responsible for the final 
cleavage of the prelamin A molecule is FACE1 or Zmpste24 (Pendas et al. 2002, 
Bergo et al. 2002). In HGPS cells, where the mutation by cryptic splice site 
activation of the pre-mRNA induces a deletion in the carboxy terminal end of 
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lamin A, the deletion would include removal of the recognition motif necessary 
for the final endoproteolytic step. This incompletely processed prelamin A 
molecule is predicted to go through initial post-translational modification steps 
but the final step is omitted and leave a prelamin A protein with a 
carboxymethylated and farnesylated cysteine in the carboxyterminal end. 
Previous in vitro studies of the post-translational processing of the lamin A 
protein predict that cells from HGPS patients have partially processed and 
truncated prelamin A protein attached to the inner nuclear membrane 
(Hennekes et al. 1994, Stuurmann et al. 1998, Capell et al. 2009). 
 
Figure 4. Multi step modification of the CaaX motif at the C-terminal end involving 
farnesylation, proteolysis and methylation processed by different enzymes. The recognition site 
for the last proteolytic step, to yield mature lamin A, is marked in blue. In HGPS this cleavage 
site is absent due to the aberrant splicing of the LMNA gene and the internal deletion of 50 
amino acids in exon 11. The subsequent protein product in HGPS is a farnesylated and 
carboxymethylated truncated prelamin A named progerin. The drawing was inspired by 
Young et al. 2006. 
 
1.6 CELLULAR PHENOTYPE IN HGPS 
Immunofluorescence studies of cells from HGPS patients with an 
antibody directed to lamin A/C show structural defects with irregularly 
shaped nuclear membranes that get more severe as the cells age in culture and 
confirms the hypothesis of a toxic effect from mutated prelamin A 
accumulation (Eriksson et al. 2003, Goldman et al. 2004). Progerin forms 
insoluble aggregates at the nuclear rim during mitosis, causes chromosome 
segregation and alters the cell cycle progression (Dechat et al. 2007, Cao et al. 
2007). Multiple structural abnormalities have been reported from studies of 
HGPS cells and include nuclear blebbing and lobulation, altered distribution of 
nuclear pore complexes, loss of peripheral heterochromatin, thickened lamina 
and mixed heteropolymer formation of A- and B-type lamins (Goldman et al. 
2004, Delbarre et al. 2006). Transcriptional misregulation and altered expression 
of various genes have been detected in cells from HGPS patients (Ly et al. 2000, 
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Csoka et al. 2004). All of these changes could result in downstream effects on 
gene regulation and DNA replication. Reduced telomere length in HGPS 
fibroblasts has also been demonstrated to mediate the onset of premature cell 
senescence trough progerin-induced DNA damage pathways (Allsopp et al. 
1992, Decker et al. 2009, Benson et al. 2010). The segmental phenotype of HGPS 
affects tissues with continuous growth (hair follicles, nails) or tissues subjected 
to high mechanical stress (joints, blood vessels). These tissues require 
permanently proliferative stem cells for repair and remodelling (skin, bone). 
Accelerated cell turnover with increased proliferation triggered by mutated 
prelamin A expression is likely to exhaust the stem cell pools. Age related 
conditions absent in HGPS like brain aging (dementia, Alzheimer disease, 
senility) and metabolic diseases (diabetes, hyperlipidemia) affect tissues that 
are well protected from mechanical forces or independent from stem cell 
regeneration (Halaschek-Wiener and Brooks-Wilson 2007). In vitro experiments 
with human mesenchymal stem cells expressing progerin demonstrated 
aberrant differentiation towards an osteogenic and apidogenic cell character 
(Scaffidi and Misteli 2006). Studies from a mouse model of HGPS that were 
recently conducted indicate that the cellular senescence, associated with HGPS, 
results in a pro-inflammatory phenotype stimulating inappropriate stem cell 
proliferation (Rosengardten et al. 2011). Downregulation of Notch and Wnt 
signalling pathways together with impaired function and depletion of stem 
cells have also been shown in mouse models with lamin mutations that 
developed typical progeroid features (Hernandez et al. 2010, Rosengardten et 
al. 2011). 
 
1.7 THERAPEUTICS FOR HGPS 
With the discovery of the HGPS mutation in the LMNA gene (De Sandre-
Giovannoli et al. 2003, Eriksson et al. 2003) the post-transcriptional processing 
of prelamin A was soon identified as a target for possible treatment of the 
disease. The processing of proteins with farnesylation motifs, like the CAAX 
box in prelamin A, can be modified by farnesyltransferase inhibitors (FTIs). 
Previously FTIs compounds without major side effects have been identified 
and applied in different cancer treatments (Reuter et al. 2000, Caponigro et al. 
2003). In HGPS the suppressed farnesylation results in a non-farnesylated 
progerin protein product. In the absence of ZMPSTE24, like in RD, the 
suppressed farnesylation results in the accumulation of non-farnesylated 
prelamin A (Young et al. 2006). Several in vitro studies have shown that FTI 
treatment reduces the proportion of misshapen nuclei and rescues nuclear 
blebbing and abnormal prelamin A and lamin A localization and aggregation 
in human HGPS and RD cells, transfected cell lines (Capell et al. 2005, Glynn 
and Glover 2005, Mallampalli et al. 2005, Toth et al. 2005, Pan et al. 2007) and 
cells isolated from lamin A mutant mouse models (Yang et al. 2005). 
Administration of FTIs to mouse models for mutant Lmna and Zmpste24 
deficient mice improved the progeroid phenotype (Fong et al. 2006, Yang et al. 
2006, Capell et al. 2008, Yang et al. 2008). In May 2007 a first clinical trial was 
enrolled including twenty-eight patients with classical HGPS from sixteen 
countries. After an initial two-month tolerance test the oral application of the 
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FTI Lonafarnib (SCH66336) was enrolled for a two-year period. This first 
clinical trail ended in December 2009 
(http://www.progeriaresearch.org/clinical-trial.html).  
While the first FTI trial was initiated additional studies have shown that 
prelamin A and progerin undergo alternative prenylation by 
geranylgeranyltransferase in the presence of FTIs (Varela et al. 2008). The 
investigators concluded that the limited in vivo benefits from FTIs application 
in LmnaHG/+ and Zmpste24-/- mice could be ascribed to this alternative pathway. 
The combined treatment of FTIs, statins and bisphosphonates has been shown 
to prevent the cross-prenylation of prelamin A and progerin and markedly 
improved the cell morphology of HGPS cells, as well as the aging like 
phenotype in Zmpste24-/- mice. The combined treatment also resulted in 
significantly prolonged animal life spans (Varela et al. 2008). After dosage 
tolerance testing with five individuals, a triple drug trial for the combined 
administration of Lonafarnib (FTI), Zoledronic Acid (bisphosphonate) and 
Pravastatin (statin) was initiated in August 2009 including forty-five children 
from twenty-four countries. The duration of the triple drug trail was planned 
over a two-year period (http://www.progeriaresearch.org/clinical-trial.html). 
 
More recently a study concentrating on an alternative age associated pathway 
has shown promising results for the potential of the antibiotic rapamycin in 
HGPS treatment (Cao et al. 2011b). The antibiotic targets a well-conserved 
aging pathway (TOR, target of rapamycin). Activated TOR has been shown to 
stimulate protein synthesis and cell growth, and regulates diverse cellular 
processes (Tsang et al. 2007). Reduced TOR signalling upon rapamycin 
treatment promotes cell maintenance processes like autophagy (Rubinsztein et 
al. 2011) and has been shown to enhance the maximum lifespan of mice, when 
administration was initiated in old animals at the age of 600 days (Harrison et 
al. 2009). In HGPS fibroblast rapamycin treatment rescued the abnormal 
nuclear morphology, slowed the progression of cellular senescence and 
reduced progerin concentrations. Rapamycin had previously been shown to 
promote the degradation of toxic compounds inside the cell (Berger et al. 2006). 
In cells from progeria patients treatment with rapamycin decreased the 
formation of insoluble progerin aggregates. Increased autophagy was 
demonstrated to support the clearance of progerin from HGPS fibroblasts (Cao 
et al. 2011b). Rapamycin is already approved for the use as an 
immunosuppressive drug and in cancer treatments (Wullschleger et al. 2006). 
Therefore rapamycin should be further tested in mouse models for HGPS and 
considered as a possible treatment option for HGPS patients. 
 
1.8 LAMINS AND AGING 
The complex processes driving physiological aging are still not 
understood and it is most likely that several molecular mechanisms are 
involved. Evidence for the involvement of lamins in aging has first been shown 
in studies on fibroblast cell cultures. The presence of low levels of progerin in 
cells from healthy individuals indicate a role of the aberrant splicing of the 
prelamin A RNA in general human aging (Scaffidi and Misteli 2006). Cultured 
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cells from individuals that have aged normally share several of the reported 
nuclear defects. The nuclear abnormalities were present in cell lines from 
young and old donors and increased with prolonged passages. However the 
nuclear changes observed in cells from older individuals appear more rapidly 
and show changes in lamin A/C localization with accumulation at the nuclear 
rim similar to HGPS patient cells (Goldman et al. 2004, Scaffidi and Misteli 
2006). In vitro studies of fibroblast from healthy donors further demonstrated 
that the amount of both, mRNA and mutated protein increases with the 
number of passage (Cao et al. 2007, Rodriguez et al. 2009). Progerin expression 
has also been found in the skin of older individuals, predominately in cells that 
have reached terminal differentiation or senescence (McClintock et al. 2007). 
Indeed, a more recent study demonstrated that telomere shortening and 
dysfunction induces the activation of progerin splicing in normal human 
fibroblasts and triggers cellular senescence (Cao et al. 2011a). 
As well as in vitro studies with human progerin expressing cells, studies 
with Zmpste24-/- mice have shown genomic instability associated with 
increased DNA damage (Liu et al. 2005, Varela et al. 2005, Liu et al. 2006). 
Defects in DNA repair mechanisms are a characteristic for progeroid 
syndromes and a hallmark of normal aging. Impaired DNA damage signalling 
activates the tumor suppressor gene p53, which triggers cellular senescence 
and accelerates an aging phenotype (Lans and Hoejimakers 2006, Manju et al. 
2006). 
 
1.9 LAMINS IN BONE 
In a study focusing on the osteoarticular system in C57BL6 wild-type 
mice lamin A/C was found in the trabecular and cortical bone. In chondrocytes 
lamin A/C was expressed at higher levels in endochondral compared to 
perichondral chondrocytes (Duque et al. 2006). Reduced expression of lamin 
A/C in aging bone was found in old mice (24 month old) compared to younger 
adult mice (4 month old). The numbers of lamin A/C expressing osteoblasts 
decreases with age from 76% in adult mice to 42% in old mice (Duque et al. 
2006).  
Knockdown of lamin A/C in Lmna-/- mice (Sullivan et al. 1999) and mouse 
models with HGPS modifications of the Lmna gene (LmnaHG/+) (Yang et al. 
2005) developed skeletal abnormalities. Common features of bone disease in 
these mouse models included growth retardation, kyphosis, bone fractures and 
poor bone mineralization (Sullivan et al. 1999, Yang et al. 2005, Yang et al. 2006). 
Recent studies of bone turnover and bone structure in Lmna-/- mice (Li et al. 
2011) showed alteration in bone mass and skeletal microarchitecture and 
reduced osteoblast and osteoclast numbers and activity. Inhibited function of 
osteogenic transcription factor Runx2 to interact in the nuclear binding 
complex affected osteoblast differentiation. Studies with knockdown of lamin 
A/C in human osteoblasts and mice deficient in Zmpste24 show inhibited 
osteoblastogenesis and simultaneously increased adipocyte differentiation 
(Akter et al. 2009, Rivas et al. 2009). The cellular mechanisms leading to these 
abnormalities in the bone remain unknown. 
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1.10 BONE DEVELOPMENT AND REMODELLING 
The skeleton is a complex metabolically active organ that is formed by 
cartilage and bone. Important functions include the maintenance of mineral 
homeostasis, mechanical support, protection of vital organs, and assistance in 
locomotion and movement through its physical connection with muscles. The 
adult human skeleton consists of 213 bones, which undergo continuous 
remodelling throughout life. Bone remodelling involves the removal of 
mineralized bone followed by the formation of new bone matrix. Three 
different cell types, osteoblasts, osteoclasts and osteocytes, are involved in bone 
maintenance (Dempster 2006). Osteoblasts are responsible for the formation 
and organization of the extracellular matrix of bone and its subsequent 
mineralization. They are derived from mesenchymal precursor cells in the 
bone marrow and activated by Wnt and BMP signalling and induced by 
osteoblastic transcription factors like Runx2 and osterix (Sp7). Further on, the 
bone microenvironment supports a continuous supply of differentiation 
factors, which directs the cells towards proliferation, maturation and terminal 
differentiation. The principal product of the mature osteoblast is type I collagen 
(90% of the protein in bone) (Karsenty et al. 2009). As a terminal differentiation 
step, some osteoblasts become trapped in lacunae within the matrix of bone as 
osteocytes (Figure 5). Osteocytes are connected by an intercellular system of 
canaliculi. These canals are responsible for intercellular communication and 
there is evidence that osteocytes regulate the response of bone to the 
mechanical environment (Bonewald and Johnson 2008). 
Figure 5. Schematic drawing of osteoblastogenesis  
Osteoblastic precursors derive from the mesenchymal stem cell lineage. Runx2 is a 
transcription factor playing a key role in cell commitment towards osteoblastogenesis. Further 
cell maturation, matrix mineralization and differentiation is controlled by frequently used 
biomarkers. Selected examples are shown. The drawing was inspired by Walkley et al. 2008. 
 
The cell types responsible for bone resorption are the osteoclasts, large and 
motile multinucleated cells located on bone surfaces. Osteoclasts are formed by 
the fusion of mononuclear cells derived from haematopoietic stem cells in the 
bone marrow. Osteoclasts are polarized cells, having a ruffled border region of 
the cell membrane that is surrounded by an organelle-free region. They adhere 
to the bone surface via integrins, which are specialized cell surface receptors. A 
pH gradient across the ruffled membrane is created by active transport 
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mechanisms, ATP-dependent proton pumps, and the enzyme carbonic 
anhydrase. Osteoclasts actively synthesize lysosomal enzymes (Teitelbaum 
2007). Bone remodelling serves to adjust bone architecture to meet changes in 
mechanical needs and helps to repair microdamages in bone matrix, 
preventing the accumulation of old bone. It also plays an important role in 
maintaining plasma calcium homeostasis. The regulation of bone remodelling 
is both systemic and local. The major systemic regulators include parathyroid 
hormone (PTH), calcitonine, 1-25 hydroxyvitamin D (calcitriol), and other 
hormones such as growth hormones, glucocorticoids, thyroid hormones, and 
sex hormones.  Furthermore, through the crosstalk between osteoclastic and 
osteoblastic cells through the RANK/RANKL/OPG system, the processes of 
bone resorption and formation are tightly coupled allowing bone formation to 
follow each cycle of bone resorption, thus maintaining skeletal integrity. 
 
The remodelling cycle consists of four phases:  
1. Activation phase 
Activation of osteoclast precursors leads to cell maturation into multinuclear 
osteoclasts. The maturation step requires the essential cytokine M-CSF 
(macrophage colony stimulating factor) produced by marrow stromal cells and 
RANKL (receptor activator of NF kappa B ligand). The ratio between RANKL 
and the blocking agent OPG (osteoprotegerin), both produced by osteoblast 
cells, regulates osteoclastogenesis.  
2. Resorption phase 
Activated osteoclasts digest old bone and form a resorption cavity. Mature 
multinuclear osteoclast cells attach to the bone surface and secrete various 
enzymes and acids (TRAP, cathepsin K, Mmp9) that cause degradation and 
dissolution of the bone mineral matrix. The resorption phase ends with 
osteoclast apoptosis and is followed by the reversal phase. 
3. Reversal phase 
A variety of coupling factors (growths factors, cytokines and hormones) lead to 
osteoclasts apoptosis and activate osteoblast proliferation and differentiation. 
Thus mononuclear preosteoblast cells appear at the resorption surface and 
induce osteoblast maturation and their attachment to the resorption cavity. 
4. Formation phase 
Bone formation is a two-step process, where osteoblasts synthesize new bone 
matrix, the osteoid, and then regulate the mineralization by releasing small 
matrix vesicles that concentrate calcium and phosphate.  
 
Under normal physiological conditions bone remodelling and the balanced 
interplay of all involved cell types is coupled, so that the relative amount of 
resorbed bone is replaced by newly formed bone matrix (Figure 6). However 
this balance is very sensitive to changes in hormone levels, mechanical stress 
and aging (Dempster 2006, Hadjidakis and Androulakis 2006, Manolagas and 
Parfitt 2010, Crockett et al. 2011).  
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Figure 6. Bone remodelling is a cellular coupled and balanced process 
Initiation of bone resorption by osteoclast is followed by osteoblast-mediated bone matrix 
formation and finally bone matrix mineralization. Multiple factors are involved in the 
activation and intracellular signalling between the involved cell types. A selection of important 
factors are indicated in blue. 
 
1.11 AN INDUCIBLE AND TISSUE SPECIFIC MOUSE MODEL SYSTEM  
The development of mouse models are a critical step in further 
understanding the pathogenesis of human diseases and in testing new forms of 
treatment. To investigate the segmental nature of HGPS with clinical features 
only present in restricted tissues will help to further understand the disease 
mechanism. In particular, since lamin A is expressed in all differentiated cells 
(Dechat et al. 2008), it still remains unclear how to explain the partial impact the 
mutation has on patients. The tissue-restricted fashion is also one of the 
challenges in the generation of representative mouse models of the human 
disease. The tetracycline-inducible systems (tet-system) are binary transgenic 
mouse model systems for spatial and temporal regulated expression of target 
genes (Gossen and Bujard 1992, Zhu et al. 2002). By choosing the tet-system in 
combination with tissue-specific promoters, the investigation of distinct disease 
mechanism in restricted HGPS affected tissues (skin and bone) is possible. In 
contrast to general knock-out or knock-in animal models, the tissue restricted 
fashion of the tet-system also enables the study of effects from sustained 
expression of the HGPS mutation in isolated organ systems. This is particularly 
interesting when investigating the long-term effects of progerin expression in 
unaffected tissues (including the brain). 
 
1.11.1 Tetracycline-inducible transactivator system 
Tetracycline-responsive transcriptional transactivator (tTA, tet-OFF) and 
reverse tetracycline-responsive transcriptional transactivator (rtTA, tet-ON) 
transgenic mice temporally regulate expression of a gene of interest. The 
transcriptional transactivators (tTA and rtTA) bind to a tetracycline responsive 
promoter element (pTRE element, tetop) that controls the transcription of a 
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target gene construct (Figure 7). The treatment of mice with tetracycline, or its 
derivate doxycycline (Dox), allows in the tet-ON system the binding of the 
rtTA to the pTRE element and subsequently allows the temporal regulation of 
gene expression. Whereas the administration of doxycycline in the tet-OFF 
system represses the binding of the tTA to the pTRE element and blocks the 
gene expression (Figure 7) (Gossen and Bujard 1992, Gossen et al. 1995). This is 
particularly interesting if one might want to study the expression of genes with 
detrimental effects during development or expression effects at later time 
points (Kistner et al. 1996). Temporal control also enables reversal studies after 
phenotype development depending on the target gene expression. 
Furthermore the fusion of tissue-specific promoter elements upstream of the 
transactivators directs their expression in a tissue-specific manner. This makes 
it possible to control the distinct spatial target gene expression inside the 
mammalian organism in in vivo model systems or in in vitro studies in single 
cells (Furth et al. 1994).  
Figure 7. The tet-Off and tet-On expression systems  
Schematic pictures of the gene regulation in the tet-system. Induction of gene expression can be 
controlled by administration of Doxycycline (Dox). In the tet-Off system tTA binds the pTRE 
element and activates transcription in the absence of Dox. In the tet-On system rtTA binds the 
pTRE element and activates transcription in the presence of Dox. The drawing was inspired by 
Gossen et al. 1995. 
 
1.11.2 Lamin minigenes 
Based on the tet-system, our laboratory generated transgenic mice with 
different minigenes of lamin A under the control of a pTRE element (tetop) 
(Figure 8) (Sagelius et al. 2008). Three lines of target mice show good expression 
levels with no leaky expression. The first two lines contain a minigene of 
human lamin A consisting of exon 1-11, intron 11 and exon 12, followed by an 
IRES, and the coding region of the green fluorescent protein (eGFP). The two 
lines only differ in codon 608, one construct carries the wild-type sequence of 
LMNA (tetop-LAwt) and the second construct carries the most common HGPS 
c.1824C>T, p.G608G mutation (tetop-LAG608G). The third line of mice carries the 
HGPS abnormal spliced cDNA lacking 150 nucleotides (tetop-LAprogerin) 
followed by an IRES, and eGFP. These transgenes enable tetop-LAwt to express 
wild-type human lamin A, tetop-LAG608G to express wild-type human lamin A 
and progerin, and tetop-LAprogerin to express exclusively progerin. 
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Figure 8. Schematic drawings of the lamin constructs 
All three constructs contain a responsive pTRE element (tetop), which regulates the expression 
of the downstream gene in the presence of a transcriptional transactivator. Construct tetop-
LAwt over-expresses wild-type human lamin A. Construct tetop-LAG608G over-expresses wild-
type human lamin A and progerin. Both constructs utilize the mouse splicing machinery for 
mRNA transcription and protein translation. Construct tetop-LAprogerin over-expresses progerin. 
An internal ribosomal entry site (IRES) allows separate translation of enhanced green 
fluorescent protein (eGFP). Nuclear export, translation and mRNA stability is supported by the 
SV40/poly A tail. The drawing was modified from Sagelius et al. 2008. 
 
1.11.3 Transactivator mice 
The work included in this thesis is based on mouse models using the 
lamin A transgenes tetopLAG608G and tetop-LAwt in combination with four 
different transactivator mice to achieve expression of the transgene in different 
organ systems. 
  
Keratin 5 promoter (paper I) 
To obtain human lamin A and progerin expression in the skin Keratin 5 
promoter mice (K5tTA, Diamond et al. 2000) were intercrossed with lamin 
minigene mice. Cytokeratins are intermediate filament proteins that play a 
central role in epithelial tissues. Keratin 5 is expressed from embryonic day 
E9.5 and onwards (Byrne et al. 1994). Bitransgenic offspring expressed the 
minigene in the skin (in the basal layer of the epidermis, sebaceous glands and 
throughout the outer root sheet of hair follicles), ameloblasts layer of the teeth, 
salivary glands, esophagus, stomach, tongue, nose cavity and trachea (Sagelius 
et al. 2008). Tetop-LAG608G+; K5tTA+ mice developed a phenotype in the skin 
with abnormal hair follicles and sebaceous gland development, fibrosis and 
loss of hypodermal adipocytes. Oral abnormalities included tooth fractures 
and inflammatory reactions of the surrounding tissues. No histopathological 
changes were detected in other organs (Sagelius et al. 2008). 
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Collagen type 1 promoter (paper II) 
Transgene expression driven by the 2.3kb collagen type 1α1 promoter (α1p-
rtTA, Liu et al. 2004) has been shown at high levels in bone, at low levels in skin 
fibroblasts, but not to be present in any other tissues. Type 1 α 1 collagen is 
expressed from embryonic day 13-14 and onwards in wild-type mice (Rossert 
et al. 1996).  
 
Osterix promoter (paper III) 
Osterix (Osx1, Sp7) is an osteoblast specific transcription factor, active during 
early osteoblastogenesis and essential for bone development. Osterix is 
expressed from embryonic day E14.5. Osx null mutant mice totally lack bone 
formation (Nakashima et al. 2002). Sp7-tTA transgenic mice enable expression 
of target genes during osteoblast differentiation (Rodda et al. 2006). 
 
Neuron specific enolase promoter (paper IV)  
The 1.8kb NSE promoter (NSE, ENO2) is expressed from embryonic day E14.0 
and throughout adulthood in the nervous system of mice (Forss-Petter et al. 
1990). It was initially generated to study specific brain regions (Chen et al. 
1998), but has been shown be active in additional tissues. Transgenic 
expression was detected at high levels in brain, bone and adipose tissue. Lower 
level expression was observed in skin and spleen (Sabatakos et al. 2000). NSE-
tTA transgenic mice allow study of the effect of mutant lamin expression 
simultaneously in a variety of affected (bone, skin, fat) and unaffected (brain) 
tissues in HGPS. 
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2 AIMS OF THE THESIS 
 
The overall aim of this thesis was to develop mouse model systems to 
elucidate the molecular mechanisms of HGPS in dental and bone tissue and to 
study effects that come with sustained progerin expression in the brain.  
 
 
 
Paper I  The specific aim of this study was to test if the HGPS mutation 
causes an irreversible phenotype in skin and teeth or if the 
elimination of progerin production would reverse developed 
disease conditions. In addition the aim was to further characterize 
the dental abnormalities observed in the mouse model. 
 
 
Paper II The initial aim of this study was to develop an inducible mouse 
model system for bone disease in HGPS. However the analysis of 
the transactivator mice revealed insufficient expression. Therefore 
the amended aim of this study was to share our negative 
experience with the tet-system. 
 
 
Paper III The specific aim of this study was the development of a mouse 
model for the spatial expression of the LMNA c.1824C>T, p.G608G 
mutation in bone tissue. The purpose was to gain a better 
understanding of the molecular mechanisms underlying the 
skeletal phenotype in HGPS. 
 
 
 Paper IV The specific aim of this study was to investigate effects of the 
expression of the HGPS mutation simultaneously in affected and 
unaffected tissues and to study long-term effects from sustained 
expression of the HGPS mutation in the brain. 
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3 NOTES ON METHODOLOGY 
Material and methods used in this thesis are described in the specific section of 
each paper and included: 
 
 
• PCR genotyping 
• Bone tissue homogenization for RNA and protein extraction 
• Reverse-transcriptase PCR on cDNA 
• Western Blotting 
• Immunohistochemistry  
• Immunofluorescence 
• Real time RT-PCR 
• Isolation of primary osteoblast explant cultures 
• 3-point bending test 
• Peripheral quantitative computed tomography (pQCT) 
• Bone mineralization assay 
• Perfusion fixation 
 
 
3.1 LABORATORY ANIMALS 
Animals were used in accordance with the guidelines for care and use of 
experimental animals at the Karolinska Institutet. Stockholms Södra 
Djurförsöksetiska Nämd approved all applied experimental procedures. The 
animals were housed in a 12-hour light/dark cycle at 20-22°C and 55-65% 
humidity in pathogen-free animal facilities at the Karolinska University 
Hospital. Doxycycline treatment and a soft food diet were applied as described 
in the respective study (paper I - paper IV). The genetic background of the mice 
and transgene integration have been discussed as possible factors for variation 
in expression levels of transactivators and target gene transcription (Dobie et al. 
1997, Opsahl et al. 2002, Robertson et al. 2002). To circumvent possible problems 
with differences in genetic background we generated congenic mouse strains 
by backcrossing the original mouse strain for ten generations to the new 
genetic background strain. For the lamin minigene tetop-LAwt and tetop-
LAG608G, both generated on FVB/N, mice were maintained on FVB/N and 
backcrossed to form B6.Cg-Tg(tetop-LAwt,-EGFP)SF1-04 and B6.Cg-Tg(tetop-
LAG608G,-EGFP)VF1-07, respectively. The transactivator mice α1p-rtTA, 
generated on C57BL/6XSJL (Liu et al. 2004) was maintained on C57BL6 and 
backcrossed to form FVB/N.Cg-Tg(α1p-rtTA). Transactivator line NSE-tTA 
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(Chen et al. 1998), provided on CD1, was maintained on CD1 and backcrossed 
to form FVB/N.Cg-Tg(NSE-tTA). Transactivator strain B6.Cg-Tg(Sp7-
tTA,tetO-EGFP/cre)1Amc/J, here referred to as Sp7-tTA (Rodda et al. 2006), 
was maintained on C57BL6. The transactivator mice K5tTA (Diamond et al. 
2000) was generated and maintained on FVB/N mice. 
 
 
3.2 OPTIMIZATION OF HUMAN LAMIN A/C 
IMMUNOHISTOCHEMISTRY ON DECALCIFIED BONE TISSUE 
Standard protocols for immunohistochemistry (IHC) on formalin fixed 
paraffin-embedded sections include application of an antigen retrieval method 
(AR) to avoid the partial or complete loss of immunoreactivity of the antigen. 
The principle of AR is based on heat incubation in an aqueous solution. This 
procedure has been shown to be the ultimate technique for standardization of 
IHC protocols. It is essential to recover the antigen from cross-linking of 
unrelated proteins caused by formalin fixation. The cellular location of the 
target antigen can be an additional challenge in AR method optimization to 
reach sufficient antigen unmasking (Shi et al. 2001).  
IHC using a mouse anti-human Lamin A/C antibody (mab3211, 
JOL2, Millipore) has been used to investigate the cellular location and 
expression pattern of the human transgene in our tissue specific mouse models. 
The protocol for lamin A/C staining of paraffin embedded sections of mouse 
tissues captured and baked on coated SuperfrostPlus Gold slides (Menzel-
Gläser) needs the use of 1mM EDTA, pH 8.0 in a pressure cooker for optimal 
antigen unmasking (Sagelius et al. 2008).  
However this AR protocol was not applicable to decalcified bone, 
since the tissue sections detached from the glass slides during the harsh boiling 
procedure. To obtain optimal antigen unmasking in skeletal tissue, different 
retrieval solutions (1mM EDTA, pH8.0 vs. 10mM Citrate buffer, pH6.0), either 
containing no or different supplemented detergents (TWEEN vs. TritonX-100) 
and multiple heating techniques for AR (water bath vs. microwave oven vs. 
heating plate), were tested. To enhance the unmasking effect of a milder AR 
method we also tested for different procedures for bone decalcification (EDTA 
vs. Formic Acid). Skeletal tissue sections tested for the protocol optimization 
included long bones (femur and tibia), rib cage, spine, lower jaw and skull.  
The best results were obtained heating the bone sections in a glass 
beaker in the presence of boiling stones and 10mM Citrate buffer pH6.0 
without any detergent supplement, as the AR solution. After deparaffinization 
and rehydration, the slides were placed in a plastic rack standing on a metal 
ring in a glass beaker. The solution was slowly brought to 95°C using a heating 
plate and kept at this temperature for 15 minutes under observation of correct 
temperature and double aluminium foil to cover the glass beaker. The beaker 
was then taken from the heat source and the solution was allowed to cool 
down to room temperature. The following staining procedure included 
blocking for endogenous peroxidase activity with methanol containing 1% 
H2O2, blocking of non-specific binding using 20% normal goat serum followed 
by mouse-to-mouse blocking reagent (Scytec Laboratories). Primary antibody 
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incubation was performed at a 1:30 dilution in PBS at 4°C over night using a 
MIST tray. The slides were washed and then incubated with a secondary 
biotin-goat-anti-mouse antibody prior to visualization and development of the 
peroxidase by ABC staining kit (Vectashield) and DAB Chromogen system 
(DakoCytomation), according to the manufactures recommendations, followed 
by brief incubation with DAB enhancer solution (Zymed). Counterstaining was 
performed with Mayer´s hemalum solution prior to dehydration and 
mounting. All washing steps were performed by carefully dipping the slides in 
PBS. From all skeletal parts tested, the staining on lower jaw sections displayed 
the most intact bone tissue with specific nuclear signals for lamin A/C located 
in osteoblasts and osteocytes. However it is recommended to include several 
slides per samples to obtain usable stained bone sections for analysis, since 
tissue damage to various degrees invariably occurs. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
To find a cure for HGPS requires that the toxic effects that come with 
progerin expression are not irrevocable for the affected tissues. The aim of this 
study was to test if progerin causes irreversible disease or if it is possible to 
reverse an existing phenotype in HGPS mice by suppressing progerin 
expression. We developed a tissue specific mouse model, based on the tet-
system, that allows the temporal regulation of the HGPS mutation. In this 
model, the administration of doxycycline suppressed the transgenic expression 
of the HGPS mutation (tetop-LAG608G). By utilizing Keratin 5 transactivator 
transgenic mice (K5tTA, Diamond et al. 2000) we directed the progerin 
production to the skin and dental tissue from the date of birth until 7 weeks of 
age. Keratin 5 is expressed in the basal layer of the skins epidermis, the outer 
root sheath of hair follicles and the ameloblast layer in the teeth (Ramirez et al. 
1994, Diamond et al. 2000, Ravindranath et al. 2003). At postnatal week 7 
bitransgenic animals, both genotype positive for K5tTA and tetop-LAG608G, 
displayed severe abnormalities including growth retardation, lower weight, 
hair thinning, skin crusting and dental changes in the incisors. The skin 
pathology included varying degrees of hyperplasia, hyperkeratosis, 
hypergranulosis and enlarged and displaced sebaceous glands. Regions with 
inflammatory cells and fibrosis were present in the dermis. Analysis of the 
distribution of keratinocytes in dorsal skin sections showed mislocalization of 
keratin 5 and 6, and the thickening of the spinous and granular layer with 
normal keratin 10 expression. Increased proliferation was detected using an 
antibody directed against phospho-histone H3 (PHH3).  
In the jaws pathological analysis revealed embedded hairs and regional 
acute inflammatory reactions in the incisors. The enamel matrix appeared non-
mineralized. Enamel is formed in a two-phase process. First ameloblast cells 
are required for secretion of enamel matrix followed by matrix mineralization 
(Long and Leininger 1999). The expression of the mutated HGPS protein in the 
ameloblast cell layer most likely leads to inhibition of enamel matrix secretion 
and improper enamel mineralization. The abnormal mineralized and softened 
enamel enables hairs to enter the tooth and cause massive inflammatory 
reactions in the surrounding tissues.  
To suppress the expression of the G608G mutation, we fed the mice 
doxycycline in drinking water from postnatal week 7 until week 20. Animals 
were terminated and tissues were collected at the age of 7, 13 and 20 weeks and 
the tissues from the different time points were analyzed and examined to check 
for phenotype improvement. That the strong transgenic expression seen in 7 
weeks old bitransgenic mice was efficiently turned off after 6 and 13 weeks of 
doxycycline treatment was demonstrated by RT-PCR and Western blot on skin 
extractions for RNA and protein. Immunofluorescence staining using a human 
lamin A/C specific antibody revealed only single positive cells remaining in a 
few hair follicles, while the expression in the ameloblast layer in the incisors 
was fully suppressed.  
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Regrowing hair and healing skin crusting was already evident after one 
week of doxycycline treatment and the external skin phenotype was 
completely recovered after 6 weeks of transgenic suppression. The skin 
pathology was almost completely normal with only a few regions of epidermal 
hypoplasia, hyperkeratosis, fibrosis and inflammatory reactions. Progressive 
fibrosis generated permanent fibrotic scars, which were hard to reverse (Wynn 
2008) and ongoing and previous wound healing most likely explained the 
remaining inflammation. In bitransgenic mice the aberrant localization of 
keratin 5 and 6 normalized with doxycycline treatment. The thickening of the 
epidermal layers and detectable increased proliferation in bitransgenic mice 
reversed and was indistinguishable from wild-type littermates. 
After 6 weeks of doxycycline treatment the overall teeth phenotype was 
milder with some remaining embedded hairs and inflammatory regions. After 
13 weeks of transgenic suppression the incisors had regenerated with only low-
grade inflammation in single areas. The transgenic suppression of progerin led 
to almost complete functional tooth regeneration in bitransgenic mice. 
Upon doxycycline treatment the animals only slightly improved their 
reduction in body weight, which remained lower compared to wild-type 
littermates. We reasoned that the suppression of transgenic expression did not 
have any effect on body weight, since the major growth phase of mice was 
already past at the time of doxycycline introduction.  
In summary this study showed that regenerative tissues including skin 
and incisors have the potential to reverse an existing phenotype when the 
expression of progerin was inhibited. The results raise the possibility for the 
development of future therapies that cure the conditions of the HGPS disease. 
Additional studies are necessary to investigate if the phenotype reversal is also 
possible in other tissues affected in HGPS. 
 
 
4.2 PAPER II 
The tet-systems are helpful tools to generate tissue specific mouse models 
that enable the temporal regulation of the expression of target genes. In this 
study we wanted to take advantage of a previously published reverse 
tetracycline regulated transactivator (rtTA) under the control of the collagen 
type 1 promoter (α1p-rtTA, Liu et al. 2004) to develop a bone specific 
expression model for the HGPS mutation.  
Expression analysis by RT-PCR showed that the expression of α1p-rtTA 
transgenic mice was too low to drive the expression of the human lamin 
minigene, since only scant amplification products could be detected after 35 
cycles of PCR. RNA and DNA samples were included to test for genomic DNA 
contamination and demonstrated that that there was no significant DNA 
contamination. Adequate cDNA samples were included as positive controls for 
the PCR assay for rtTA, human lamin A and progerin.  
On protein level we performed Western Blot on bone protein extracts and 
immunofluorescence staining on primary osteoblast explant cultures with a 
human lamin A/C specific antibody. No transgenic expression driven by α1p-
rtTA could be detected on Western films or osteoblast cells for any of the tested 
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backgrounds. Positive control samples were included from tetop-LAG608G+; 
Sp7tTA+ mice (paper III) and demonstrated the functionality of the 
experiments. 
To prevent possible expression variation or limitations based on genetic 
mouse background (Dobie et al. 1997) we generated congenic mouse lines for 
the involved transgenic mice. α1p-rtTA was generated on C57BL6 and 
backcrossed to FVB/N.Cg-Tg(α1p-rtTA). Tetop-LAG608G (Sagelius et al. 2008) 
was generated on FVB/N and backcrossed to B6.Cg-Tg(tetop-LAG608G). Tetop-
LAwt was generated on FVB/N and backcrossed to B6.Cg-Tg(tetop-LAwt). All 
breedings were preceded for ten generations and enabled the analysis of 
transgenic expression on mixed (FVB/N; C57BL6) and two pure genetic 
backgrounds, FVB/N and C57BL6 respectively. When we intercrossed α1p-
rtTA transgenic mice with tetop-LAG608G transgenic mice, expressing human 
lamin A and progerin, no phenotype differences were detectable despite the 
genotype and genetic background of the offspring. 
Reasons for the inadequate expression of α1p-rtTA transgenic mice were 
not further investigated. Long-term instability dependent on epigenetic 
modification, unexpected expression pattern, positional- and dosage 
dependent effects and problems due the usage of small construct sizes have 
been reported and discussed before by others as explanations for variable 
efficiencies reported for the tet-system (Furth et al. 1994, Böger and Gruss 1999, 
Fedorov et al. 2001, Ryding et al. 2001, Robertson et al. 2002, Lee et al. 2006, Sun 
et al. 2007, Bao-Cutrona and Moral 2009).  
In summary, in this study, we reported our negative experience with a 
previously functional transactivator mice. To share unfortunate research 
approaches with the scientific community is of importance to raise cautions in 
the use of established model systems and to reinforce the obligation for 
controls. To monitor the long-term stability of generated transgenic mouse 
lines will help to eliminate dysfunctional expression systems and contribute to 
save valuable resources.  
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
The work included in this thesis demonstrated that the tissue restricted 
inducible model systems are useful tools to test for the possibility of phenotype 
reversal after disease manifestation. The expression of progerin in tissues with 
a high turnover like the skin and the regenerative teeth did not cause incurable 
damage. Investigation of the recovery potential of tissues and organ systems 
affected in HGPS gives hope for the development of future treatments of 
children suffering from progeria. 
 
For the initial approach in the second study we concluded that the 
previously functional collagen type 1 specific reverse tetracycline-controlled 
transactivator failed to target the HGPS mutation to the bone. Possible 
mechanisms leading to the inactivity of the promoter were not further 
investigated. However we believe that the report of our negative experience is 
an important contribution to the scientific community. Especially in the context 
of established model systems that are widely used and commonly shared it is 
of importance to raise caution and to reinforce the need for controls. 
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